Wellosia®; Prioritizing our patients' well-being

After pioneering the first-generation S1P modulators as fingolimod, NanoAlvand is honored to introduce the launching of ozanimod, a selective second-generation drug of this category. Wellosia®️ launch proudly comes at the earliest opportunity following the first FDA approval of the brand which is indicated for relapsing forms of multiple sclerosis (MS) and moderately to severely active ulcerative colitis (UC).

Adhering to the principle of "the less is more", Wellosia® delivers the lowest effective dose with enhanced potency and efficacy due to our advanced manufacturing process. Furthermore, our innovative starter pack simplifies the treatment regimen, ensuring a seamless experience for our patients.